Fulgent is a technology-driven Biopharma services company boasting a robust portfolio of clinical diagnostic, research solutions and R&D capabilities. Our clinical diagnostic and BioPharma business units provide a wide array of services including molecular diagnostic testing, comprehensive NGS genetic testing, RNASeq, targeted DNA / RNA panels (FFPE, Liquid Biopsy, Heme), single cell and spatial analysis (10x Genomics), proteomics (Olink) and top-tier anatomic pathology laboratory services (Immunohistochemistry (IHC), RNAscope (ISH), Akoya, Flow Cytometry). These offerings are meticulously crafted to support biomarker development in immuno-Oncology research complemented with actionable diagnostic insights, ultimately enhancing the quality of patient care. With a dedicated focus on patient screening and enrollment testing, biomarker analysis, and companion diagnostics for clinical research, Pharma Clinical trials, and contract research, Fulgent’s BioPharma Services cater to the specific needs of the pharmaceutical industry. With facilities situated in the US, China, and Australia, our overarching mission is to revolutionize the genomic diagnostic landscape, positioning ourselves as a fully integrated precision medicine company poised to drive advancements in healthcare. Fulgent’s latest step forward to this commitment is approval for the largest CE-marked Clinical Exome gene panel for genetic testing, underscoring our dedication to meeting the highest standards of regulatory compliance & quality. | Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike.
DNAnexus
DNAnexus: Accelerating the Future of Human Genetics and Precision Medicine The advancement of human genetics hinges on our ability to navigate and interpret vast, complex datasets. As research pushes the boundaries of discovery, from single-gene disorders to population-scale genomics, the challenges of data management, analysis, and collaboration have grown exponentially. DNAnexus is at the forefront of this evolution, providing a secure, scalable, and collaborative cloud-based platform designed to meet the unique needs of the global life sciences community. We are on a journey to democratize how researchers and clinicians work with clinico-genomic data, transforming it into actionable discoveries that improve patient outcomes. Unifying Complex, Multi-Modal Data at Scale DNAnexus leads the way in the management and analysis of multi-omics data to accelerate breakthroughs in precision medicine. Our Precision Health Data Cloud empowers life science organizations to seamlessly integrate complex genomic, transcriptomic, proteomic, clinical, and real-world datasets. This unified approach provides a holistic view of human biology, enabling researchers to uncover novel insights into disease mechanisms, identify new therapeutic targets, and power the next wave of drug discovery and development. The platform is built to handle data at scale, providing the robust foundation necessary for everything from rare disease analysis to large-scale population health studies. Fostering Secure Collaboration and Innovation Scientific progress is a collaborative endeavor. The DNAnexus platform provides a secure and collaborative environment where data can be combined and analyzed, fostering innovation without compromising on security or compliance. We enable this through solutions like Trusted Research Environments (TREs), which provide regulatory-grade spaces for dynamic collaboration and efficient, compliant submissions. Our unwavering commitment to the highest security standards ensures that sensitive data, privacy, and intellectual property are protected, allowing your teams to focus on what matters most: accelerating scientific discovery. Harnessing AI-Powered Analytics for Actionable Insights Built upon this foundation of integrated data and security, DNAnexus offers robust, AI-driven analytics to unlock the full potential of your research. By leveraging advanced AI and machine learning tools, our platform helps you move beyond raw data to find meaningful patterns and actionable insights. This empowers your organization to speed the journey from research to patient impact, simplifying regulatory compliance and driving innovations that improve healthcare for all. Engage with DNAnexus at ASHG 2025 to explore how our pioneering data analysis and management solutions can empower your research and help translate genetic discoveries into the future of precision health.
DNA Genotek, Inc.
OraSure Technologies, Inc. transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample collection solutions. OraSure, together with its subsidiaries, DNA Genotek and Sherlock Biosciences, is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. Our portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers.
Common Fund Data Ecosystem (CFDE)
The Knowledge Center (KC) integrates data and knowledge generated by ground-breaking research programs in the NIH Common Fund Data Ecosystem. Use the KC to see curated and precomputed analyses of data within and across Common Fund projects.
Broad Clinical Labs
Broad Clinical Labs (BCL) is a subsidiary of the Broad Institute that provides a range of research and clinical services – including CLIA licensed and CAP accredited genomic data generation and advanced genomic analysis – both for the Broad research community and for the rest of the world.
BioAro
BioAro Inc. is a leading biotechnology company specializing in whole genome sequencing and advanced genetic analysis. With a strong commitment to personalized medicine, BioAro leverages cutting-edge genomic technologies to provide individuals, healthcare professionals, and researchers with comprehensive insights into genetic health, disease predisposition, and personalized wellness strategies. At the core of BioAro’s services is its whole genome sequencing platform, which delivers high-precision genetic data that empowers users to make informed health decisions. The company’s offerings extend beyond raw data by providing advanced interpretation through proprietary bioinformatics pipelines and AI-driven analytics. By transforming complex genetic information into actionable insights, BioAro enables early disease detection, risk assessment, and tailored treatment recommendations. BioAro is dedicated to bridging the gap between genomic science and real-world application by making genetic testing accessible and understandable. Its services cater to a diverse clientele, including individuals interested in proactive health management, clinicians seeking precision medicine solutions, and researchers aiming to advance genetic discoveries. The company also collaborates with pharmaceutical and healthcare organizations to support drug development and personalized therapeutics. With a focus on innovation and data security, BioAro upholds the highest standards of accuracy and confidentiality. Its state-of-the-art sequencing facilities adhere to rigorous quality controls, ensuring reliable results that users can trust. As the demand for personalized medicine grows, BioAro continues to expand its capabilities, staying at the forefront of genomic advancements to improve health outcomes and revolutionize the future of healthcare. | BioAro Inc., established in 2021, is a Canadian biotechnology company headquartered in Calgary, Alberta. The company specializes in precision health, health span, and longevity, integrating genomics, artificial intelligence (AI), and blockchain technologies to deliver personalized healthcare solutions. BioAro’s mission is to revolutionize personalized healthcare through its cutting-edge technologies, including the BioPhenome Lab, BioHealth software solutions, Biospan clinics, and biotech devices. The company’s vision focuses on extending human healthspan by integrating innovative approaches for a healthier future. BioAro operates internationally, with Headoffice in Calgary, Canada; and offices in Dubai, United Arab Emirates; and Almelo, The Netherlands, and United Kingdom reflecting its commitment to making personalized medicine accessible worldwide. BioAro aims to transform healthcare from reactive disease management to proactive health optimization, empowering individuals to take control of their health and well-being. | BioAro Inc. is a Calgary-based precision health biotechnology company advancing real-time, AI-driven multi-omics solutions for personalized medicine. Its PanOmiQ™ platform integrates genomic, epigenomic, pharmacogenomic, microbiome, and clinical data to deliver rapid, scalable insights that support early disease detection, tailored treatment strategies, and predictive healthcare. BioAro’s ecosystem improves clinical decision-making and expands precision medicine markets.
Baylor Genetics
As a pioneer of precision medicine for over 45 years, Baylor Genetics is a leading diagnostic genomics partner offering a full spectrum of clinically relevant genetic testing, including Whole Genome Sequencing, Whole Exome Sequencing, and focused panels. Through a joint venture of H.U. Group Holdings, Inc. and Baylor College of Medicine, Baylor Genetics combines rapid and comprehensive precision diagnostics options with the support of genetic counselors to help clinicians avoid a lengthy diagnostic odyssey for their patients, guide medical management, and ensure no patient with a genetic disorder gets left behind. Baylor Genetics’ testing menu covers family planning, pregnancy, neonatal and pediatric testing, oncology, and many other specialized testing options. Located in Houston’s Texas Medical Center, Baylor Genetics serves clients in 50 states and 16 countries.
AutoGen, Inc.
AutoGen offers expert DNA/RNA extraction solutions for both high- and low-volume labs, including outsourced processing services, highly customizable automated instruments, and consumable kits. Our solutions help biobanks, universities, contract research organizations (CROs), and diagnostic centers increase DNA and RNA processing throughput, meet commitments, and advance the business of science. Workflows: Our instrumentation and consumables are configured to yield the most significant amount of usable nucleic acid. AutoGen workflows include Magnetic Bead-Based Isolation, Column-Based Isolation, and Precipitation-Based Isolation. Extraction Services: Looking for a customized and flexible extraction provider? We offer specialized laboratory services for the extraction of DNA and RNA. Access the latest in automated extraction equipment, chemistries, and protocols from a team of US-based extraction experts dedicated to your project’s success. Sample Storage, ID, and Handling: As the North American distributor of LVL Technologies, we offer a wide array of advanced sample storage solutions, including 2D barcoded tubes, barcode readers, decapping and recapping tools, and other essential equipment. By incorporating these products, labs can reduce sample handling times, ensure optimal sample security, and minimize costly misidentification errors. Saliva & Microbiome Collection: AutoGen is the U.S. partner for Isohelix products, including DNA & RNA saliva collection devices. Contact us to discover how Isohelix products can assist with sample collection, preservation, and isolation. Visit www.AutoGen.com for more details.
American Board of Medical Genetics and Genomics (ABMGG)
The mission of the ABMGG is to serve the public and the medical profession by promoting and assuring standards of excellence in medical genetics.